After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
Merck KGaA’s failure with its MS drug cladribine six years ago triggered a long and painful revamp in its R&D group, earning the German pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
